NANJING, China, March2nd, 2019 TransThera Biosciences Co. Ltd today announced that it has initiated preclinical development of its proprietary lead compound TT-00920. TT-00920 is a first-in-class, orally bioavailable drug candidate for the treatment of heart failure disease. “The advancement of TT-00920 into preclinical development is an important milestone for TransThera. Compelling preclinical results support that TT-00920 can improve cardiac function in both HFrEF (heart failure withreduced ejection fraction) and HFpEF (heart failure with preserved ejectionfraction). We hope to bring a breakthrough therapy to patients suffering from this severe disease with our innovative drug. " said Dr. Frank Wu, founder and CEO of TransThera. The company expects to submit INDs in the US in the fourth quarter of 2019.
Heart failure is characterized by the heart’s inability to pump an adequate supply of blood to the body, causing the disruption of major body functions. Heart failure is a global pandemic affecting at least 37 million people worldwide and is increasing in prevalence.It is the leading cause of hospitalization and readmission in people age 65 and older. Heart failure remains a major unmet medical need of human beings.